Eran Andrechek, Ph.D.

517-884-5042
andrech1@msu.edu

Andrechek Lab Website

Research Interests
The progression of human breast cancer and cancer in general, is a process that is unique among each individual. The mutations that occur in each individual tumor give rise to tumors that are largely heterogeneous when compared to each other. The heterogeneity present within cancer presents a significant obstacle in both elucidating the various mechanisms of transformation and in the development of therapies. When recent work that elucidated the mutational spectrum and pathway activation is considered with the mindset of progression towards therapy, the importance of recognizing the particular genomic signature of an individual tumor becomes quite apparent.

Work in my laboratory is focused on understanding mammary tumor development and employs a number of methods to do so, ranging from animal models to computational analysis of gene expression data.  We use an integrative method whereby we use bioinformatic methods to make predictions for the role of specific signaling pathways in tumor biology that are then tested using model systems.

Current research projects in the laboratory include an analysis of heterogeneity in mouse models of breast cancer through signaling pathway signatures, a determination of the role of the E2F transcription factors in several models of breast cancer, characterization of the development of the mammary gland in the absence of the E2Fs and modeling individualized therapy in a transgenic system.
 

Selected Publications
 

Jonathan Rennhack, Briana To, Harrison Wermuth and Eran R. Andrechek, (2017) Mouse models of breast cancer share amplification and deletion events with human breast cancer, Journal of Mammary Gland Biology and Neoplasia, In Press. doi: 10.1007/s10911-017-9374-y.

Jing-Ru Jhan and Eran R. Andrechek (2017) Effective personalized therapy for breast cancer based on predictions of cell signaling pathway activation from gene expression analysis, Oncogene, In Press. doi: 10.1038/onc.2016.503.

Deanna Acosta, Pilib O’Broin, Daniel Hollern, John M Greally, Aaron Golden, Eran Andrechek, Teresa Wood, Cristina Montagna (2016) Transcriptome Profiling Supports LPA Receptor Activity in Enriched Mammary Epithelial Cell Populations During Postnatal Development, Sci Rep. Nov 3;6:35810. doi: 10.1038/srep35810.

Jing-Ru Jhan and Eran R. Andrechek (2016) Stat3 regulates tumor latency and growth rate but not metastasis in Myc induced breast cancer, Oncotarget, Aug 29. doi: 10.18632/oncotarget.11667.

Jonathan Rennhack and Eran R. Andrechek (2016) Conserved E2F mediated metastasis in mouse models of breast cancer and HER2 positive patients, Oncoscience, DOI: 10.18632/oncoscience.259

Lance D. Miller, Eric Jimenez, Jeff A. Chou, Michael A. Black, Cristin Print, Julia Chifman, Angela Alistar, Thomas Putti, Xiaobo Zhou, Davide Bedognetti, Ashok Pullikuth, Jonathan Rennhack, Eran R. Andrechek, Sandra Demaria, Ena Wang, Francesco M. Marincola (2016) Gene Classifiers of Immune Responsiveness Suggest Immunogenic Subtypes of Breast Cancer. Cancer Immunology Research, Jul;4(7):600-10. doi: 10.1158/2326-6066.CIR-15-0149.

Jason Turpin, Ian Swanson, Jonathan Rayment, Josie Ursini-Siegel, Zachary Hartman, Joe Gray, Obi Griffith, Lewis Chodosh, Jonathan Rennhack, Eran Andrechek, John Ozcelik, Michael Hallett, Gordon Mills, and William Muller (2016) The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer, Oncogene, May 9. doi: 10.1038/onc.2016.129.

Chanele Cyr-Depauw, Jason Northey, Zhifeng Dong, Sean Cory, Michael Hallett, Jonathan Rennhack, Eran Andrechek, and Peter Siegel (2016) Chordin-like 1 suppresses BMP4-induced breast cancer cell migration and invasion, MCB, May 2;36(10):1509-25. doi: 10.1128/MCB.00600-15.

Conserved E2F mediated metastasis in mouse models of breast cancer and HER2 positive patients. Rennhack J, Andrechek ER. Oncoscience DOI: 10.18632/oncoscience.259

PTPRD regulates Myc induced breast cancer metastasis after E2F2 loss. Yuwanita I, Barnes D, Monterey M, O’Reilly S, Andrechek ER. Oncotarget DOI: 10.18632/oncotarget.5690

The E2F transcription factors regulate tumor development and metastasis in a mouse model of metastatic breast cancer. Hollern DP, Cardiff R, Andrechek, ER. Molecular and Cellular Biology 2014 Sep;34:3229-43.

A genomic analysis of mouse models of breast cancer reveals molecular features of mouse models and relationships to human breast cancer. Hollern DP, Andrechek ER. Breast Cancer Research, 2014; 16:R59

HER2/Neu tumorigenesis and metastasis is regulated by E2F activator transcription factors. Andrechek ER. Oncogene. 2013 Dec 23. doi: 10.1038/onc.2013.540. [Epub ahead of print] PMID:    24362522

T58A Myc induced tumors have reduced dependency upon Kras mutations and initiate tumors with similarities to human-claudin low breast cancer. Hollern D, Yuwanita I, Andrechek ER. Oncogene, 2012 Apr 23. doi: 10.1038/onc.2012.142.

Prediction and genetic demonstration of a role for activator E2Fs in Myc-induced tumors. Fujiwara K, Yuwanita I, Hollern DP, Andrechek ER. Cancer Res. 2011 Mar 1;71(5):1924-32.

Mouse models of cancers: opportunities to address heterogeneity of human cancer and evaluate therapeutic strategies. Andrechek ER, Nevins JR. J Mol Med. 2010 Nov;88(11):1095-100. Epub 2010 Jun 24. Review.

Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential.
Andrechek ER, Cardiff RD, Chang JT, Gatza ML, Acharya CR, Potti A, Nevins JR. Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16387-92.

Anchorage-independent cell growth signature identifies tumors with metastatic potential. Mori S, Chang JT, Andrechek ER, Matsumura N, Baba T, Yao G, Kim JW, Gatza M, Murphy S, Nevins JR. Oncogene. 2009 Aug 6;28(31):2796-805.

Patterns of cell signaling pathway activation that characterize mammary development. Andrechek ER, Mori S, Rempel RE, Chang JT, Nevins JR. Development. 2008 Aug;135(14):2403-13.